Clinical Trial Results:
            A phase 2a, randomised, double-blind, placebo-controlled, cross-over, single and multiple dose study to assess the effects of imeglimin on nicotine-induced endothelial dysfunction in young non-smoker healthy male subjects.
    
|     Summary | |
|     EudraCT number | 2016-003215-35 | 
|     Trial protocol | DE | 
|     Global completion date | |
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | |
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | |
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | |
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    19 Aug 2021
                             | 
|     First version publication date | 
                                    19 Aug 2021
                             | 
|     Other versions | |
|     Summary report(s) | Summary of results | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
